PLX (Protalix BioTherapeutics) Insider Ownership: 6.08 % (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLX Protalix BioTherapeutics Inc PLX
54 GF Score
Price $2.34
GF Value $2.20
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Protalix BioTherapeutics Insider Ownership?

Protalix BioTherapeutics PLX +2.18% 54 Insider Ownership is 6.08 % as of Aug. 18, 2026. GuruFocus rates PLX with a GF Score™ of 54/100 and a GF Value™ of $2.20 (Fairly Valued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Protalix BioTherapeutics's insider ownership is 6.08%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Protalix BioTherapeutics's Institutional Ownership is 20.56%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Protalix BioTherapeutics's Float Percentage Of Total Shares Outstanding is 96.12%.

Protalix BioTherapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Protalix BioTherapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protalix BioTherapeutics Insider Ownership Chart

Protalix BioTherapeutics Historical Data

The historical data trend for Protalix BioTherapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 5.92 6.07 6.07 6.07 6.02 6.09 6.09 6.08 6.08 6.08
PLX
54GF Score
Protalix BioTherapeutics Inc PLX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protalix BioTherapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 6.08 % mean?
Protalix BioTherapeutics (PLX) has a Insider Ownership of 6.08 % as of Aug. 18, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Protalix BioTherapeutics and its competitors.
Is Protalix BioTherapeutics' Insider Ownership too high?
Protalix BioTherapeutics' current Insider Ownership is 6.08 %. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Insider Ownership compare to GLSI and DTIL?
Protalix BioTherapeutics' Insider Ownership of 6.08 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Insider Ownership is 6.08 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current Insider Ownership is 6.08 %. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Insider Ownership is 6.08 % as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protalix BioTherapeutics (PLX) Overvalued in 2026?

Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued. The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20. GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.

Key valuation signals for PLX:

  • Insider Ownership: 6.08 %
  • GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protalix BioTherapeutics Business Description

Other Exchanges PBDA:Germany
Address 2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score

Get the complete analysis for PLX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price
$2.20
GF Value